Register Login

Cogent Biosciences Inc (COGT)

  • Event
  • June 10, 2022, 11:12 UTC

(85% Positive) COGENT BIOSCIENCES, INC. (COGT) Announces Enrollment Update for reduction Due to Patient Enrollment Issues, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Oct. 2, 2025, 6:11 a.m.

    📋 COGENT BIOSCIENCES, INC. (COGT) - Clinical Trial Update

    Filing Date: 2022-06-10

    Accepted: 2022-06-10 07:12:08

    Event Type: Clinical Trial Update

    Event Details:

    Cogent Biosciences Inc (COGT) Announces Clinical Trial Update Cogent Biosciences Inc (COGT) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: reduction, shown
    • Diseases/Conditions: serum tryptase, Vienna
    • Clinical Stage: Phase 2, clinical trial
    • Collaboration: Cogent
      • targeting FGFR2 and ErbB2. Cogent Biosciences is based in Cambridge, MA and Boulder, CO. Visit our website for more information at www.cogentbio.com. Follow Cogent Biosciences on social media: Twitter and LinkedIn. Information that may be important to investors will be routinely posted on our website and Twitter. Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995

    💼 Business Developments:

    No business developments data available.

    Structured Data:

    • Company Name: Cogent Biosciences Inc
    • CIK: 0001622229
    • Ticker Symbol: COGT
    • Period End Date: 2022-06-07
    • Document Type: 8-K

Search

News categories